ZENAS BIOPHARMA, INC. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$10M
R&D
$168M
D&A
$56K
Operating Income
$-383M
EBITDA
$-383M
Interest Expense
$7M
Interest Income
$12M
Other Income/Expense
$417K
Pretax Income
$-378M
Tax Provision
$-79K
Net Income
$-378M
Operating Margin
-3830.6%
Net Margin
-3777.4%
Effective Tax Rate
0.0%
Deferred Tax Assets
$1M
Deferred Tax Liabilities
$1M
DTA Valuation Allowance
$204M
Tax Credit Carryforwards
$26M
NOL Carryforwards
$65M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.0%
ETR Foreign Differential (pp)
0.2%
Operating Lease Cost
$1M
Revenue YoY Variation
100.0%
Income YoY Variation
-133.7%